Author
Muni Kumar Meravath is a seasoned Healthcare Market Research Analyst with over 6 years of experience in the healthc.....
Folate Receptor Market: Competitive Landscape, Pipeline, and Market Analysis 2023
Folate receptors bind folate and reduce folic acid derivatives and mediate delivery of tetrahydrofolate to the interior of cells. Folate receptors (FRs) are glycoproteins that exist in several isoforms (1, 2). The FR-α and the FR-β are both anchored in the cell membrane by a glycosyl-phosphatidyl-inositol domain. The FR-α is expressed at a few sites of normal epithelial membranes. For instance, in the proximal tubule cells of the kidneys and in a variety of solid cancer types of epithelial origin. Cancer types with the highest frequency of FR-α expression are ovarian cancer(90%), endometrial cancer (90%), brain (90%), lung cancer (78%), and renal carcinomas (75%). Moreover, FR-expression in cancer of the head and neck (52%), breast (48%), stomach (38%), and colon-rectum (32%) was found at intermediate frequencies. The mechanism of action (MOA) of the Folate Receptor antagonists is directed against folate receptor alpha (FRα). The small molecule, DM4, is a microtubule inhibitor attached to the antibody via a cleavable linker. Upon binding to FRα, they internalized followed by intracellular release of DM4 via proteolytic cleavage. DM4 disrupts the microtubule network within the cell, resulting in cell cycle arrest and apoptotic cell death. Folate Receptor antagonists are used in the treatment of endocrine disorders, ovarian cancer, adenoma, carcinoma, and lung and respiratory disorders among others. Increased prevalence of endocrine diseases and ovarian cancer are the key drivers for the Folate Receptor market. For instance, according to the World Health Organization 2020, around there were more than 3 lakhs cases of ovarian cancer worldwide. The introduction of newer products by market players may look for opportunities that have a big impact on comprehensive research and development in Folate Receptor antagonists. For instance, ImmunoGene’s Elahere injection launched for the treatment of ovarian cancer. Moreover, to address the difficulties in therapy, numerous market participants are developing innovative compounds. For instances, Novartis Vynfinit (Vintafolide) for the indication of ovarian cancer is under the various stages of clinical studies.
Key Market Developments:
Approved Drug Molecules and Brand Names for Folate Receptor:
Drugs under the Pipeline for Folate Receptor:
Clinical Activity and Developments of Folate Receptor:
Up until July 2023, there will be about 16 companies with over 34 compounds that focus on various forms of cancers and endocrine disorders. For these molecules, hundreds of clinical trials are being conducted and majority are in phase-2, phase-3 clinical trials by the players across the globe. For instance,
Molecule Name |
Number of Studies |
Farletuzumab (MORAB-003) |
12 |
Vynfinit (Vintafolide) |
10 |
TPIV200 |
4 |
Farletuzumab Ecteribulin (Morab-202) |
4 |
Luveltamab Tazevibulin (STRO-002) |
3 |
The molecules such as Elahere (Mirvetuximab Soravtansine-Gynx) Injection developed by ImmunoGen is a folate receptor alpha (FRα)-directed antibody and microtubule inhibitor conjugate; specifically approved for the treatment of adult patients with FRα positive, platinum-resistant epithelial ovarian, fallopian tube, or primary peritoneal cancer, who have received one to three prior systemic treatment regimens through the intravenous administration. Eisai’s Farletuzumab (MORAB-003) is a folate receptor antagonist for the indication of solid tumours.
Report Benchmarks |
Details |
By Region |
USA Germany France United Kingdom Spain Italy Japan Rest of World |
Download Free Sample Report
ImmunoGen’s Elahere (mirvetuximab soravtansine-gynx) injection is the only FDA- approved Folate Receptor antagonist.
Projected sales growth of Elahere expected to reach US$ 615 million by FY2029.
ImmunoGen, Eisai, Novartis are few leading market players in Folate Receptor Market.
Endocrine disorder, ovarian cancer, adenoma, carcinoma, and lung and respiratory disorders are the major indication of Folate Receptor antagonists.
There are a total of 19 molecules that are in the Phase-1, Phase-2 and Phase-3 clinical development.
Key Market Players